logo.jpg
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
August 17, 2022 13:19 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 17, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
logo.jpg
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
August 16, 2022 14:26 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 16, 2022 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...
logo.jpg
Capital Increase in Genmab as a Result of Employee Warrant Exercise
August 16, 2022 14:22 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 16, 2022 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 46,441 shares as a consequence of the exercise of employee warrants. The...
logo.jpg
Transactions in connection with share buy-back program
August 15, 2022 03:42 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 15, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
logo.jpg
Genmab Announces Financial Results for the First Half of 2022
August 10, 2022 11:01 ET | Genmab A/S
August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase...
logo.jpg
Genmab Improves Its 2022 Financial Guidance
August 08, 2022 12:33 ET | Genmab A/S
Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance...
logo.jpg
Transactions in connection with share buy-back program
August 08, 2022 04:18 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...
logo.jpg
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
August 05, 2022 06:45 ET | Genmab A/S
COPENHAGEN, Denmark; August 5, 2022  Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumorsExpanded collaboration leverages Genmab’s...
logo.jpg
Major Shareholder Announcement
August 02, 2022 14:46 ET | Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; August 2, 2022 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
logo.jpg
Transactions in connection with share buy-back program
August 01, 2022 07:41 ET | Genmab A/S
Company Announcement COPENHAGEN, Denmark; August 1, 2022 – Genmab A/S (Nasdaq: GMAB). On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant...